Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire•13/11/2026•07:00 ET
0
Key Highlights
- ➤JADE101 EVERGREEN Phase 3 registrational trial expected to initiate in Q4 2026
- ➤JADE301 Phase 1 trial expected to initiate in Q4 2026
- ➤Cash, cash equivalents, and investments totaled $475.7 million; runway expected into Q4 2028
- ➤Q3 net loss $35.1 million versus $25.2 million year over year
- ➤JADE101 JUNIPER interim data expected in Q2 2027
Expert Statements
Tom Frohlich, Chief Executive Officer of Jade
“The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones. We are preparing to initiate the Phase 3 EVERGREEN trial of JADE101 ahead of schedule, reflecting both our rapid execution and our continued conviction in JADE101’s potential best-in-class profile. We also expect to advance JADE301 into the clinic this quarter, which, alongside JADE101 and JADE201, will give us three clinical-stage programs heading into 2027. With multiple clinical catalysts expected across our pipeline next year, we see significant opportunities to further demonstrate the differentiated profiles of our programs and ultimately deliver meaningful new therapies for patients with autoimmune disease.”
* JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026
* JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027
Get started
Create a free account to read the full story.